U.S. FDA Accepts for Priority Review the Supplemental

Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from...

Related Keywords

Denmark ,Japan ,Valby ,Hovedstaden ,Tokyo ,Copenhagen ,Køavn ,Canada ,New Jersey ,United States ,Netherlands ,American ,Hematol Hemoter ,Andrew Carlsen ,David Freundel ,Abbvie Biotechnology Ltd ,Exchange Commission ,Drug Administration ,Data From The Observational National Lymphocare Study ,Global Communications Corporate Affairs ,Twitter ,Exposition Of The American Society Hematology ,Lymphoma Research Foundation ,Priority Review ,Biologics License Application ,Prescription Drug User Fee Act ,Chief Executive Officer ,Annual Meeting ,American Society ,Breakthrough Therapy Designation ,Follicular Lymphoma ,Senior Director ,Global Communications ,Vice President ,Media Release ,Annual Report ,Y Shaped Genmab ,Abbvie Biotechnology ,Opin Med ,Bras Hematol ,Subsequent Therapy ,Data From ,Observational National Lymphocare ,Treatment Patterns ,Patients With Diffuse Largeb Cell Lymphoma ,Relapsed Follicular Lymphoma ,Marginal Zone Lymphoma ,Jacobsens Vej ,Copenhagen Stock Exchange Gen ,Genmaba S ,